貝達藥業(300558.SZ):一季度淨利預增140%-160%
格隆匯4月9日丨貝達藥業(300558.SZ)披露2020年第一季度業績預告,預計歸屬於上市公司股東的淨利潤1.24億元至1.34億元,同比增長140%至160%。
報告期內,公司產品埃克替尼銷售繼續放量,預計歸屬於上市公司股東的淨利潤同比大幅上升。經過多年的紮實工作和艱苦努力,公司始終以患者為中心,以臨牀需求為導向,開展了一系列的埃克替尼臨牀研究,為臨牀醫生提供了充分的針對非小細胞肺癌(NSCLC)患者治療療效及安全性的循證醫學證據,埃克替尼的差異化優勢不斷積累,在非小細胞肺癌(NSCLC)靶向藥市場贏得了很好的口碑,樹立了國產創新藥的品牌形象,從而為銷量的持續增長奠定了基礎。同時,為了保障疫情期間的藥品供應,經銷商也相應提高了流通系統的安全庫存量。
在報告期,公司新藥鹽酸恩沙替尼的優先審評程序正常推進,鹽酸恩沙替尼一線治療ALK陽性非小細胞肺癌(NSCLC)患者的全球多中心Ⅲ期臨牀研究順利進行。同時MIL60Ⅲ期、BPI-D0316Ⅱ期、CM082腎癌Ⅲ期等多項註冊臨牀研究按計劃進行,BPI-23314、BPI-17509等項目陸續進入臨牀研究,公司正全力推進在研項目,爭取早日實現產品價值。
報告期內,非經常性損益對淨利潤的影響金額預計為-100.00萬元至100.00萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.